mynth
← DATABASE
06/2013LBO

Péters Surgical acquired by Eurazeo

FRANCE Life Sciences / Medical Devices / Medical Consumables EV €20–50M

Context

The acquisition of Peters Surgical by Eurazeo PME is a strategic move that reflects the investment firm's commitment to supporting the growth and development of medium-sized enterprises in the healthcare sector. With its strong track record of investing in medical device companies, Eurazeo PME will provide Péters Surgical with the financial and strategic support it needs to continue expanding its product offerings and increasing its international presence. The deal is expected to be completed by the end of July 2013, with Eurazeo PME acquiring approximately 90% of Péters Surgical's capital. The company's management team, including President and CEO Jean-Marc Chalot, will retain a significant stake in the business and will continue to play a key role in driving its growth and development. The acquisition is expected to provide Péters Surgical with the resources it needs to pursue its strategic objectives, including expanding its product lines and increasing its presence in emerging markets. With its strong reputation for quality and innovation, Péters Surgical is well-positioned to become a leading player in the global medical device industry, and Eurazeo PME's support will be instrumental in helping the company achieve its full potential.

Péters Surgical, which reported an EBITDA margin of [members only] in 2012, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Péters Surgical is a French company that designs, manufactures, and distributes a range of single-use medical devices for operating rooms. The company's primary product lines include surgical sutures, wall reinforcements, and drains. Founded in 1926 and based in Bobigny, Péters Surgical has established a strong presence in the French market and exports its products to over 75 countries worldwide. The company's business model is centered on building close relationships with its clients, including public hospitals and private clinics, and it has developed a network of agents and distributors to support its international sales efforts. With a workforce of approximately 350 employees, Péters Surgical has demonstrated significant growth in recent years, with revenue increasing from 24 million euros in 2009 to 37 million euros in 2012. The company's products are designed to meet the specific needs of surgical professionals, and its commitment to quality and innovation has enabled it to establish a strong reputation in the medical device industry.

Ent. Value

€20–50M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

5x–12x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2012
€25–50M
€5–25M
[members only]
2011
€25–50M
€5–25M
[members only]

Other operations with Péters Surgical

Other operations with Péters Surgical
DateAcquirerTargetCountrySector
03/2024ADVANCED MEDICAL SOLUTIONS GROUPPÉTERS SURGICALFRANCEMedical Consumables

Other operations with Eurazeo

Other operations with Eurazeo
DateAcquirerTargetCountrySector
04/2016EURAZEO / MERIEUX EQUITY PARTNERSNOVACAPFRANCESpecialty Chemicals
03/2016EURAZEOGLION INSTITUTE / LES ROCHESSWITZERLANDEducation Providers
11/2015EURAZEOPLANET PAYMENTIRELANDFintech & Payments
09/2014EURAZEOCOLISÉEFRANCENursing Homes
03/2014EURAZEODESIGUALSPAINFashion & Apparel
02/2014EURAZEOVIGNAL GROUPFRANCEAuto Parts & Systems
01/2014EURAZEOASMODEE GROUPFRANCEConsumer Products
07/2013EURAZEOEVERNEXFRANCEMSP (Managed Services)
06/2013EURAZEOIES SYNERGYFRANCEBatteries & EV Tech
06/2011EURAZEOMONCLERITALYFashion & Leather Goods

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
10/2013ARDIANLABORATOIRES ANIOSFRANCEMedical Consumables
07/2013CHARTERHOUSEDOC GENERICIITALYGenerics / Labs
06/2013BC PARTNERSANTELLIQFRANCEAnimal Health
01/2013ELITECH GROUPVITAL DIAGNOSTICSUNITED STATESDiagnostic Equipment
08/2012BC PARTNERSAENOVA GROUPGERMANYCDMO
05/2011AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIALAGARRIGUEFRANCEImplants & Prosthetics
09/2010SPARRING CAPITALIMV TECHNOLOGIESFRANCER&D Biotech
09/2009THE CARLYLE GROUPMARLE GROUPFRANCEImplants & Prosthetics
04/2007ASTORGETHYPHARMFRANCEPharma & Biotech
01/2006EDMOND DE ROTHSCHILD CAPITAL PARTNERSACTEONFRANCEMedical Devices

REFERENCES

Valuation range: EV €20–50M

Revenue range: €25–50M

EBITDA range: €5–25M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 5x - 12x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Péters Surgical by Eurazeo are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: péters surgical

FAQ

How was the acquisition of Péters Surgical by Eurazeo valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €20–50M band, its EV/EBITDA multiple within the 5x - 12x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Péters Surgical’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Péters Surgical generated annual revenue estimated in the €25–50M range and EBITDA in the €5–25M bracket (FY 2012). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.